A phase 1 open label dose escalation study evaluate the safety of a single escalating dose of NX-CP105 (human adult bone marrow derived somatic cells [hABM-SC] administered by endomyocardial injection to cohorts of adults 30-60 days following acute myocardial infarction.

Trial Profile

A phase 1 open label dose escalation study evaluate the safety of a single escalating dose of NX-CP105 (human adult bone marrow derived somatic cells [hABM-SC] administered by endomyocardial injection to cohorts of adults 30-60 days following acute myocardial infarction.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Sep 2008

At a glance

  • Drugs Human adult bone marrow-derived somatic cell therapy Neuronyx (Primary)
  • Indications Myocardial infarction
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Sep 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top